The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Belova A.N.

Privolzhsky Research Medical University

Sheiko G.E.

Privolzhsky Research Medical University

Ruina E.A.

Privolzhsky Research Medical University

Makarova A.E.

City Clinical Hospital No. 3

Dubchenko E.A.

Veresaev City Clinical Hospital

Kukushkina A.D.

Zhadkevich City Clinical Hospital;
Pirogov Russian National Research Medical University

Ponevezhskaya E.V.

Zhadkevich City Clinical Hospital

Lisogorskaya E.V.

Zhadkevich City Clinical Hospital

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies

The diagnostic effectiveness of criteria for neuromyelitis optica spectrum disorders in the Russian clinical practice

Authors:

Belova A.N., Sheiko G.E., Ruina E.A., Makarova A.E., Dubchenko E.A., Kukushkina A.D., Ponevezhskaya E.V., Lisogorskaya E.V., Boyko A.N.

More about the authors

Read: 1430 times


To cite this article:

Belova AN, Sheiko GE, Ruina EA, et al. . The diagnostic effectiveness of criteria for neuromyelitis optica spectrum disorders in the Russian clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7‑2):16‑25. (In Russ.)
https://doi.org/10.17116/jnevro202412407216

Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Hormonal contraception methods and multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30
Epidemiology of multiple scle­rosis in the city of Novo­sibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

References:

  1. Jarius S, Aktas O, Ayzenberg I, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (OCD) — revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023;270(7):3341-3368. https://doi.org/10.1007/s00415-023-11634-0
  2. Kümpfel T, Giglhuber K, Aktas O, et al. Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) — revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024;271(1):141-176.  https://doi.org/10.1007/s00415-023-11910-z
  3. Wingerchuk DM, Banwell B, Bennett JL, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.  https://doi.org/10.1212/WNL.0000000000001729
  4. Simaniv TO, Vasil’ev AV, Askarova LSh, Zakharova MN. Neuromyelitis optica and neuromyelitis optica spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):35-48. (In Russ.). https://doi.org/10.17116/jnevro20191191035
  5. Kanikannan MA, Arepareddy PK, Mathukumalli NL, et al. Validation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of South Indian patients. Mult Scler Relat Disord. 2019;35:164-169.  https://doi.org/10.1016/j.msard.2019.07.024
  6. Traboulsi A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomized, double-blind, multicenter, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412.  https://doi.org/10.1016/S1474-4422(20)30078-8
  7. Novikova ES. Possibilities of therapy for neuromyelitis optica spectrum disorders. Rossiiskyi jurnal detskoi nevrologii. 2021;16(4):49-58. (In Russ.). https://doi.org/10.17650/2073-8803-2021-16-4-49-58
  8. Wingerchuk DM, Hogancamp WF, O’Brien PCet al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53(5):1107-1114. https://doi.org/10.1212/wnl.53.5.1107
  9. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489. https://doi.org/10.1212/01.wnl.0000216139.44259.74
  10. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815.  https://doi.org/10.1016/S1474-4422(07)70216-8
  11. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8-12.  https://doi.org/10.1186/1742-2094-10-8
  12. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.  https://doi.org/10.1016/S1474-4422(22)00431-8
  13. Rees JH, Rempe T, Tuna IS, et al. Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Magn Reson Imaging Clin N Am. 2024;32(2):233-251.  https://doi.org/10.1016/j.mric.2023.12.001
  14. Kim HJ, Paul F, Lana-Peixoto MA, et al. Guthy-Jackson Charitable Foundation NMO International Clinical Consortium & Biorepository. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015;84(11):1165-1173. https://doi.org/10.1212/WNL.0000000000001367
  15. Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler. 2014;20(6):695-704.  https://doi.org/10.1177/1352458513506953
  16. Carnero Contentti E, Soto de Castillo I, Daccach Marques V, et al. Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. Mult Scler Relat Disord. 2018;20:109-114.  https://doi.org/10.1016/j.msard.2018.01.001
  17. He M, Wu L, Huang D, Yu S. Application of the 2015 neuromyelitis optica spectrum disorders diagnostic criteria in a cohort of Chinese patients. Mult Scler Relat Disord. 2020;46:102459. https://doi.org/10.1016/j.msard.2020.102459.
  18. Hamid SH, Elsone L, Mutch K, et al. The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Mult Scler. 2017;23(2):228-233.  https://doi.org/10.1177/1352458516663853
  19. Hyun JW, Jeong IH, Joung Aet al. Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder. Neurology. 2016;86(19):1772-1779. https://doi.org/10.1212/WNL.0000000000002655
  20. Papeix C, Beigneux Y, Maillart E, et al. A comparative evaluation of different neuromyelitis optica spectrum disorder sets of criteria. Eur J Neurol. 2020;27(11):2250-2256. https://doi.org/10.1111/ene.14414
  21. Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol. 2019;32(3):385-394.  https://doi.org/10.1097/WCO.0000000000000694
  22. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. Mult Scler. 2017;23(2):182-184.  https://doi.org/10.1177/1352458516688352
  23. Marignier R, Hacohen Y, Cobo-Calvo A, et al. The incidence and prevalence of neuromyelitis optica: a systematic review. Int J MS Care. 2013;15(3):113-118.  https://doi.org/10.7224/1537-2073.2012-048
  24. Marignier R, Bernard-Valnet R, Giraudon P, et al. NOMADMUS Study Group. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology. 2013;80(24):2194-2200. https://doi.org/10.1212/WNL.0b013e318296e917
  25. Pyatova ED, Jordanskaya NA. Introductory course in medical statistics: textbook. Nizhny Novgorod: NizhGMA Publishing House; 2009. (In Russ.).
  26. Borisow N, Kleiter I, Gahlen A, et al. NEMOS (Neuromyelitis Optica Study Group). Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Mult Scler. 2017;23(8):1092-1103. https://doi.org/10.1177/1352458516671203
  27. Zandoná ME, Kim SH, Hyun JW, et al. The onset location of neuromyelitis optica spectrum disorder predicts the location of subsequent relapses. Mult Scler. 2014;20(14):1908-1911. https://doi.org/10.1177/1352458514528763
  28. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicenter study of 175 patients. J Neuroinflammation. 2012;9:14-23.  https://doi.org/10.1186/1742-2094-9-14
  29. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383-392.  https://doi.org/10.1038/nrneurol.2010.72
  30. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology. 2012;78(9):665-671.  https://doi.org/10.1212/WNL.0b013e318248dec1

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.